Trelegy ellipta sales 2024?

Information on Trelegy Ellipta sales specifically for the full year 2024 is not yet available as the year is ongoing. However, available data indicates recent performance.

What were Trelegy Ellipta's recent sales figures?

For the first quarter of 2024, Trelegy Ellipta achieved global sales of $575 million, representing a 7% increase compared to the same period in the previous year [1]. This performance contributed to GSK's respiratory franchise, which saw overall growth [1].

How does Trelegy Ellipta's performance compare to other respiratory treatments?

Trelegy Ellipta is a key product within GSK's respiratory portfolio. Its consistent sales growth in early 2024 suggests it is maintaining its market position. The company's respiratory franchise, which includes other products, has been a significant driver of its overall financial results [1].

When did Trelegy Ellipta's patents begin to expire?

Information regarding specific patent expiry dates for Trelegy Ellipta is available through specialized databases. DrugPatentWatch.com tracks patent information for various medications, which can provide details on when patent protection is set to end [2]. This information is crucial for understanding potential market entry for generic or biosimilar versions of the drug.